Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Chow

Infectious Disease Bay Shore, NY Medical Doctor

NPI 1063778355 CMS profile 2789455

40 E Main St, Bay Shore, NY 11706

Open in the dashboard

General payments

$5,202

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Chow of Bay Shore, NY is reported in the CMS Open Payments database as having received $5,202 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,231 62
2024 General $1,259 58
2023 General $1,008 48
2022 General $1,047 51
2021 General $410 12
2020 General $30 2
2019 General $217 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Chow
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Robert Chow were reported at $1,231. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Robert Chow Infectious Disease median Middle half National median
2019 $217 $190 $60–$862 $163
2020 $30 $124 $32–$606 $114
2021 $410 $148 $38–$905 $132
2022 $1,047 $166 $50–$834 $149
2023 $1,008 $171 $57–$787 $160
2024 $1,259 $176 $52–$752 $164
2025 $1,231 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,369 66 payments
  2. Melinta Therapeutics, Inc. $1,203 56 payments
  3. Merck Sharp & Dohme Corporation $853 53 payments
  4. Gilead Sciences, Inc. $315 14 payments
  5. ViiV Healthcare Company $294 16 payments
  6. Janssen Pharmaceuticals, Inc $274 11 payments
  7. Shionogi Inc $244 9 payments
  8. Pfizer Inc. $206 9 payments
  9. Paratek Pharmaceuticals, Inc. $151 5 payments
  10. Smith+Nephew, Inc. $151 3 payments
  11. Other $142 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,031 240 payments
  2. Education $171 8 payments
Products named General payments · program years 2019–2025
  1. Kimyrsa $1,097 53 payments
  2. DALVANCE $986 45 payments
  3. Orbactiv $970 47 payments
  4. TEFLARO $750 38 payments
  5. AVYCAZ $741 37 payments
  6. Rezzayo $709 37 payments
  7. ZERBAXA $691 44 payments
  8. Vabomere $617 26 payments
  9. DIFICID $446 26 payments
  10. RECARBRIO $419 24 payments
  11. Other $2,427 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

999

Median for Hospitalist: 109

Drug cost

$751,817

Median for Hospitalist: $6,399

Branded share of claims

39.2%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 80 $359,739
Daptomycin Generic 175 $201,161
Ertapenem Ertapenem Sodium Brand 119 $65,739
Descovy Emtricitabine/Tenofov Alafenam Brand 13 $30,846
Isentress Raltegravir Potassium Brand 14 $28,105
Meropenem Generic 55 $18,507
Ceftriaxone Ceftriaxone Sodium Brand 86 $11,768
Vancomycin Hcl Generic 65 $7,986
Cefepime Hcl Generic 22 $6,919
Ampicillin Sodium Generic 24 $6,828

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$564,630

Of which drugs: $129,006

Medicare patients

1,233

Average age 78

Services billed

100,928

680 women, 553 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 67%
Diabetes 55%
Chronic kidney disease 54%
Heart failure 45%
Atrial fibrillation 43%
Depression 42%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dalbavancin, 5 mg J0875 Office 11 9,575 $115,842
Injection, ertapenem sodium, 500 mg J1335 Office 39 663 $6,007
Injection, daptomycin, 1 mg J0878 Office 20 84,100 $2,498

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $278
$278 — 9,575
Rezzayo
  • Melinta Therapeutics, Inc. $93
$93 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $93
$93 — —
AVYCAZ
  • AbbVie, Inc. $92
$92 — —
TEFLARO
  • AbbVie, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record